For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

SC24 Practicing changing trial results presented at the ASTRO 2020 meeting

Treating spinal lesions with fewer, higher doses of radiation reduces pain more effectively

The results show that using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. More than twice as many patients treated with stereotactic body radiation therapy (SBRT) reported an enduring, complete reduction in pain, compared to those treated with conventional radiation.

More >>
 

Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.

More >>
 

CCTG Director Dr. Janet Dancey, elected to Canadian Academy of Health Sciences

The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.

More >>
 
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

More >>
 

Planned trials

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

MA40

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

PR21

PLUDO (Prostate Lutetium/Docetaxel): Study of 177Lu-PSMA-617 vs Docetaxel in Pts with Met Castration-Resistant Prostate Ca & PSMA-Positive Disease

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BL13F

A Prospective Feasibility Sub-Study of BL13 - [e-PRISM]

More >>

CX6

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III

More >>

GCC1

Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours

More >>

I234G

Carboplatin in Metastatic Castration-Resistant Prostate Cancer

More >>

IC8

COV-IMMUNO - Immunization with IMM-101 vs Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

More >>

ICC1

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

More >>

ME15

1cm vs 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT-II)

More >>

PM1S

Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients

More >>

SC27

Impact of COVID-19 Pandemic on Cancer Patients During Treatment and Survivors

More >>

CCTG is recruiting for a Patient Representative Volunteer Role

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth).

This is a volunteer role for membership on the Head & Neck General Committee, the Head & Neck Executive Committee, and the CCTG Patient Representative Committee. Patient Representatives participate in all aspects of their Site Committee activities, and collectively all Site Committee Patient Representatives make up the CCTG Patient Representative Committee.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 

Publications

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;OGCOBrien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;

More >>

Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial (ONLINE)

Cancer n/a, 2020
Moku P;Shepherd L;Ali SM;Leitzel K;Parulekar WR;Zhu L;Virk S;Nomikos D;Aparicio S;Gelmon K;Drabick J;Cream L;Halstead ES;Umstead TM;Mckeone D;Polimera H;Maddukuri A;Ali A;Nagabhairu V;Poulose J;Pancholy N;Spiegel H;Chen BE;Lipton A;

More >>

The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)

Cancer Epidemiol Biomarkers Prev 29: 1692, 2020
Cheng E;Zhang S;Ou FS;Mullen B;Ng K;Saltz LB;Niedzwiecki D;Mayer RJ;Mowat RB;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Meyerhardt JA;Fuchs CS;

More >>

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial (ONLINE)

The Lancet , 2020
Parker CC;Clarke NW;Cook AD;Kynaston HG;Petersen PM;Catton C;Cross W;Logue J;Parulekar W;Payne H;Persad R;Pickering H;Saad F;Anderson J;Bahl A;Bottomley D;Brasso K;Chahal R;Cooke PW;Eddy B;Gibbs S;Goh C;Gujral S;Heath C;Henderson A;Jaganathan R;Jakobsen H;James ND;Kanaga Sundaram S;Lees K;Lester J;Lindberg H;Money-Kyrle J;Morris S;O'Sullivan J;Ostler P;Owen L;Patel P;Pope A;Popert R;Raman R;Roder MA;Sayers I;Simms M;Wilson J;Zarkar A;Parmar MKB;Sydes MR;

More >>

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial (ONLINE)

JAMA Oncology , 2020
Sridhar SS;Blais N;Tran B;Reaume MN;North SA;Stockler MR;Chi KN;Fleshner NE;Liu G;Robinson JW;Mukherjee SD;Rahim Y;Winquist E;Booth CM;Nguyen NT;Beardsley EK;Alimohamed NS;McDonald GT;Ding K;Parulekar WR;

More >>

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;O'Brien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;

More >>

Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial (ONLINE)

Breast Cancer Res Treat , 2020
Ho V;Pasquet R;Luo S;Chen G;Goss P;Tu D;Lazarus P;Richardson H;

More >>

Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients

Journal of Neuro-Oncology 149: 65 - 71, 2020
Climans SA;Brandes AA;Cairncross JG;Ding K;Fay M;Laperriere N;Menten J;Nishikawa R;O'Callaghan CJ;Perry JR;Phillips C;Roa W;Wick W;Winch C;Mason WP;

More >>